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Beta-thalassemia is a group of frequent genetic disorders resulting in the synthesis of little
or no b-globin chains. Novel approaches are being developed to correct the resulting a/b-
globin chain imbalance, in an effort to move beyond the palliative management of this
disease and the complications of its treatment (e.g. life-long red blood cell transfusion, iron
chelation, splenectomy), which impose high costs on healthcare systems. Three ap-
proaches are envisaged: fetal globin gene reactivation by pharmacological compounds
injected into patients throughout their lives, allogeneic hematopoietic stem cell trans-
plantation (HSCT), and gene therapy. HSCT is currently the only treatment shown to
provide an effective, definitive cure for b-thalassemia. However, this procedure remains
risky and histocompatible donors are identified for only a small fraction of patients. New
pharmacological compounds are being tested, but none has yet made it into common
clinical practice for the treatment of beta-thalassemia major. Gene therapy is in the
experimental phase. It is emerging as a powerful approach without the immunological
complications of HSCT, but with other possible drawbacks. Rapid progress is being made in
this field, and long-term efficacy and safety studies are underway.Beta-thalassemia was first discovered in the Mediterranean
Basin and is highly prevalent in countries also affected by
malaria, but human migration has resulted in the establish-
ment of this disease in many areas of the world [1]. All pa-
tients display defects of hemoglobin (Hb) beta-chainerging Diseases and Innov
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ranging from severe anemia to an absence of clinical symp-
toms. Classification and severity grading are based princi-
pally on spontaneous Hb levels and clinical tolerance,
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7e10 g/dL and do not require regular transfusion. They may
display a broad spectrum of clinical signs, depending on the
degree of alpha to non-alpha globin chain imbalance and
several genetic and environmental factors. They may suffer
from numerous complications, including pulmonary hyper-
tension, thrombotic events, infection, endocrine dysfunction
and leg ulcers [2]. Patients with beta-thalassemia major
require regular transfusions of red blood cells to survive [3].
However, repeated transfusions cause iron overload, with
life-threatening complications, such as endocrine dysfunc-
tion, cardiomyopathy, liver disease and, ultimately, prema-
ture death. In the absence of transfusion, patients with beta-
thalassemia major die within the first five years of life, and
even with transfusions, only 50e65% of patients live beyond
the age of 35 years in high-income countries [4e6]. Research
is highly active [Fig. 1], and progress has been made towards
the development of new drugs, including biological products,
some of which have recently reached the clinical trial stage.Pharmacological therapies
Trace amounts of fetal Hb (HbF) persist into adulthood, ac-
counting for less than 1% of total Hb in most adults [7].
However, HbF levels may exceed this threshold in some in-
dividuals. Beta-thalassemia patients with inherited persistent
high levels of HbF production have a milder clinical course
than other patients with this disease, andmany do not require
transfusions [8]. Therapeutic approaches reactivating HbF,
and increasing its concentration, are, therefore, attractive.
Variant HbF levels are highly inheritable [9]. Genome-wide
association studies (GWAS) have compared individuals with
low and persistently high levels of HbF, with the aim of
identifying quantitative trait loci (QTL) to serve as a source of
plausible candidate causal genes or regulatory regions [10]
accounting for the persistence of g-globin gene expression.
Strong associations between HbF level and single-nucleotide
polymorphisms (SNPs) have been identified for at least four
genomic loci, including the HBB (hemoglobin, beta) and ol-
factory receptor gene clusters on chromosome 11p15.4, the
chromosome 6q23.3 HBS1L-MYB (HBS1-like translational
GTPase - v-myb avianmyeloblastosis viral oncogene homolog)
intergenic region (HMIP), the BCL11A (B-cell CLL/lymphoma
11A) locus on chromosome 2p16.1, and the KlF1 (Kruppel-like
factor 1) gene on chromosome 19p13.13 [11e18]. Variants at
the HMIP-BCL11A-HBB loci account for 20e50% of the vari-
ability of HbF levels and the relative contributions of these
variants differ between ethnic groups [19e23].
The 158C > T (rs7482144) SNP located at the XmnI site of
the HBG2 (hemoglobin gamma G gene) promoter in the HBB
locus was shown to be correlated with HbF levels in pioneer-
ing studies conducted on normal individuals and patients
with sickle cell disease or b-thalassemia [24e27]. In the
absence of a demonstrated functional role for this site, it has
been suggested that HbF phenotype is modified by cis-linked
elements located elsewhere in the b-globin cluster and in
linkage disequilibrium with this SNP [28,29]. Indeed, a quasi-
palindromic structure located at the 50 DNAse hypersensitive
site 4 (HS4) of the locus control region (LCR), a polymorphismof which is in linkage disequilibrium with the XmnI site [28],
may affect direct or indirect interactions with the transcrip-
tional repressor BCL11A [30]. This transcriptional repressor
directly regulates HbF levels during the globin switch after
birth [31]. Erythroid-specific BCL11A knockdown blocks the
silencing of fetal globin genes [32], and BCL11A SNPs associ-
ated with HbF level variations (located in intron 2) colocalize
with target sites for erythroid transcription factors [33]. The
KLF1 transcription factor represses g-globin expression by
activating BCL11A, with haploinsufficiency causing high HbF
levels [17,34,35]. The MYB gene is a key regulator of the bal-
ance between proliferation and differentiation during eryth-
ropoiesis [36]. It regulates HbF levels through an as yet
undetermined mechanism [37,38]. The intergenic HBS1L-MYB
region contains MYB enhancer sites and DNA targets for
erythroid transcription factors [39]. Genetic variants associ-
ated with the persistence of HbF, located in a 24 kb region of
HMIP [15], affect MYB expression [16] by reducing erythroid
transcription factor binding and long-range promoter activa-
tion [40].
The regulatory transcription factors involved in g-globin
gene regulation or F-cell differentiation and survival are
potentially of considerable interest as targets for increasing
HbF levels. However, it remains difficult to modulate the
function of factors other than enzymes or signal-dependent
nuclear factors by disrupting DNA/protein or protein/protein
interactions [41] and such modulation is particularly prob-
lematic for factors with important non-erythroid functions
[42]. Furthermore, any interference with erythroid transcrip-
tion factors may result in the inappropriate disruption of
erythropoiesis. Efforts are being made to design endonucle-
ases capable of precisely disrupting the genomic sequences
involved in the erythroid-specific expression of g-globin re-
pressors, as a means of activating HbF, but this remains a
difficult challenge [43].
The S-phase cell-cycle inhibitor hydroxyurea (HU) has
proved clinically effective in patients with sickle cell anemia
(SCA) [44,45]. It is also of clinical benefit to some patients with
b-thalassemia intermedia and it reduces the need for trans-
fusions in a subset of individuals with b-thalassemia major
[46e53]. However, side effects have been reported, including
cytopenia, hyperpigmentation, weight gain, opportunistic in-
fections, azoospermia in approximately 80% of men (even
years after the end of treatment), and marked hypomagnese-
mia [54]. There is little or no risk of leukemia [55], but HU is
believed to be teratogenic [54]. Given the potential adverse ef-
fects and reported efficacy in only a subset of patients, it is
important to identify likely responders and nonresponders
before initiating treatment, to ensure that prescriptions are
efficiently targeted. The increase in HbF levels following HU
injection in patients with b-thalassemia major seems to be
correlatedwith theXmnI polymorphism [46,49,50,53], although
this result has not been confirmed by all studies [47]. The cor-
relation is less evident for non-transfusion-dependent thal-
assemia [48,51,52]. This is problematic, as treatments aiming
to increase Hb levels by a few grams per deciliter are clearly
morepromising for the treatment of patientswith thalassemia
intermedia than for the treatment of transfusion-dependent
patients. Baseline HbF level is clearly correlated with BCL11A
SNP markers [11,12,14] and levels of the g-globin repressor
Fig. 1 e Current and future therapies for beta-thalassemia major. Hemoglobin disorders account for almost 5% of deaths in
children under the age of five years. For a minority of patients, mostly in high-income countries, current therapies include life-
long monthly supportive red blood cell transfusions together with iron chelation or curative allogeneic HSC transplantation. The
pharmacological induction of fetal hemoglobin and gene therapy are currently at the experimental stage. Top left: Conventional
therapy includes regular red blood cell transfusions and iron chelation with injectable (Deferoxamine) or oral (Deferiprone or
Deferasirox) drugs. Bottom left: Gamma-globin chain inducers aim to reduce the need for red blood cell transfusions. A number of
drugs have been tested, including cytotoxic compounds and epigenetic regulators. The first drug shown to increase g-globin
expression was the demethylating agent 5-azacitidine. Small-chain fatty acid derivatives, including arginine butyrate, have also
been shown to increase g-globin expression most likely by inhibiting histone deacetylation. Hydroxyurea is the only drug
currently approved for g-globin induction. It acts through multiple mechanisms. Its cytotoxic activity is thought to accelerate the
differentiation process and to stimulate cellular stress response pathways, leading to an overall increase in the number of F cells.
Gamma-globin gene induction by other cytotoxic agents may also be mediated by this stress response. Erythropoietin (EPO) has
proliferative and anti-apoptotic properties. The combined administration of recombinant EPO together with cytotoxic drugs can
be beneficial for patients with low baseline EPO levels. Future treatments may target the transcription factors involved in g-globin
repression, such as BCL11a and KLF1. BCL11a is an essential transcription factor involved in g-globin downregulation. It binds to
intergenic regions of the HBB locus, promoting long-range interactions with the LCR that favors b-globin expression. It recruits
histone deacetylase to repress g-globin. KLF1 is a strong inducer of b-globin expression that also activates BCL11A transcription
when produced in large amounts in adult cells. KLF1 may itself be stimulated by c-Myb. Bottom right: Allogeneic transplantation
with related or unrelated donor cells from cord blood units, mobilized peripheral blood or bone marrow is currently the only
curative treatment, provided that a compatible donor can be found. Yet the risks of graft versus host disease and transplant
rejection restrict the use of this procedure. Top right: Gene therapy is a promising single-dose medicine, without the need for
immunosuppressive conditioning and graft versus host disease prophylaxis. It is potentially applicable to all patients. Studies
evaluating safety and efficacy are currently underway and have already reported encouraging results. Studies of larger numbers
of patients are required before any firm conclusions about efficacy and safety can be drawn. Long-term effectiveness/risk/cost
ratios will need to be carefully addressed.
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hemoglobinopathies [57]. However, only a few studies have
investigated the correlation between polymorphisms and the
HbF response to HU treatment, and conflicting results have
been obtained [53,58e60]. In a study of beta-thalassemia pa-
tients of Iranian origin, polymorphisms of intron 2 of BCL11A
were found to be correlatedwith the response toHU treatment
[53]. By contrast, in studies including patients with SCA,
BCL11A levels and SNPs were not found to be correlated with
HbF induction after HU treatment [58e60], suggesting an
important role for BCL11A in controlling baseline HbF levels,
but with other factors required for HU to increase HbF levels. It
has also been shown that intergenic HBS1L-MYB SNPs are not
correlated with HU treatment [53,60].
SNPs of HBG2, HBS1L-MYB and BCL11A can be used for the
rapid screening of disease severity in newborns and to provide
more personalized care [61], but pharmacogenomics ap-
proaches do not distinguish between patients respondingwell
and poorly to HU treatment [62]. The criteria for treatment
should therefore not be based on these genetic characteristics.
A number of genes involved in translation, ribosomal as-
sembly and chromosome organization, but with no known
function in normal, physiological b-globin switching, are
deregulated in the erythroid cells of SCA patients treated with
HU [58]. As recently suggested, the difference between weak
and strong responses to HU may lie in the constitutive acti-
vation of genes involved in the stress response and terminal
erythroid differentiation, and of genes protecting cells against
stress-induced apoptosis in patients with strong responses
[63]. Thus, the culture of erythroid progenitors and in-
vestigations of the expression profile of specific genes may
make it easier to distinguish responders from nonresponders
before the initiation of HU treatment in beta-thalassemia
patients, but this possibility requires further study. Short
trial periods on HU therapy (<3months) are currently required
to identify the patients most likely to respond to this treat-
ment [48].
A number of other non-selective compounds, including
cytotoxic compounds, short-chain fatty acid derivatives
(SCFAD) and erythropoietin (Epo), have been investigated and
evaluated in clinical trials [64]. Some are thought to act via
epigenetic mechanisms. This is not surprising given (i) the
strong correlation between epigenetic modification and the
developmental pattern of globin gene expression [65e67] and
(ii) the finding that some of the variation of HbF synthesis in
adults may be linked to loci sensitive to epigenetic regulation
[68]. However, the mechanisms of action of these compounds
are not fully understood because they belong to several cate-
gories, including cytotoxic and hypomethylating agents (5-
azacytidine, decitabine, HU), cytotoxic and histone deacety-
lase inhibitors, such as butyrate derivatives, and anti-
apoptotic factors (Epo or Kit ligand) [69].Allogeneic hematopoietic stem cell
transplantation
Conventional therapies (red blood cell transfusion and iron
chelation) improve the quality of life and survival of patients
[70], but allogeneic hematopoietic stem cell transplantation(HSCT) currently offers the only hope of a definitive cure for
patients with beta-thalassemia. HSCT was first successfully
performed more than 30 years ago [71,72]. Several trans-
plantation centers have since tried to categorize risk factors
and to diversify HSCT procedures, with the aim of treating
more patients, decreasing the risks of morbidity and mortal-
ity, and improving overall thalassemia-free survival. Several
factors have been shown to affect patient outcome: severity
criteria before transplantation (hepatomegaly, portal fibrosis
and irregular chelation history), age at transplantation, stem
cell source (peripheral blood, bone marrow, cord blood), his-
tocompatibility (related matched, unrelated matched, mis-
matched, haploidentical), preparative conditioning regimen
and pretransplant eradication of marrow hyperplasia. Despite
the lack of evidence from randomized clinical studies
comparing donor sources and/or conditioning regimens,
HSCT is now widely accepted as a curative treatment [73]
resulting in a long-term quality of life similar to that of the
general population and higher than that of conventionally
treated patients without active disease [74,75].
In a pioneering study, the group of Pesaro [76,77] assigned
young patients to three classes according to the absence or
presence of one, two or three risk factors before trans-
plantation: hepatomegaly > 2 cm, portal fibrosis and irregular
chelation history (class 1 ¼ no risk factor, class 2 ¼ one or two
risk factors and class 3 ¼ three risk factors). The trans-
plantation of HLA (human leukocyte antigen)-matched sibling
donor (MSD) cells into young class 1 or class 2 individuals on
myeloablative conditioning (14 mg/kg busulfan þ 200 mg/kg
cyclophosphamide) and cyclosporin for graft-versus-host
disease (GVDH) prophylaxis, gave excellent results (82e90%
disease-free survival), but this treatment was highly toxic in
pediatric class 3 patients (only 55% survived) [78,79]. Overall
survival (OS) was increased to 74% by decreasing the dose of
cyclophosphamide to below 200 mg/kg, but the probability of
graft rejection (GR) remained high (35%) and event-free sur-
vival (EFS) remained low (49%) [80], probably due to inade-
quate immunosuppression and/or a failure to eradicate the
massive erythroid hyperplasia.
Due to long-term exposure to iron overload, most patients
over the age of 16 years have class 3 characteristics, and early
attempts to treat them by transplantation, with high-dose
cyclophosphamide regimens, were highly disappointing. All
six patients died from graft failure or graft-versus-host dis-
ease (GVDH) in one study [81]. Use of a preparative regimen
adapted to the risk factors identified in young patients
improved the outcome for adult individuals, but OS remained
low (63e65%). Rejection-free survival was slightly better than
that for young class 3 patients (60e62%), mostly because
rejection rates were lower in adults than in children, for un-
known reasons [80e82]. Overall, the results obtained for class
3 patients weremuchworse than those for patients with class
1 or class 2 beta-thalassemia. Chronic active hepatitis at the
time of transplantation had a strong negative impact on OS in
adults [82].
Very few changes to the treatment of class 1 and 2 pediatric
patients have occurred in recent years, with the exception of
thiotepa, which is used to reduce rejection rates in patients
under the age of four years [83]. A subgroup of young class III
patients, those under the age of eight years, with
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to have a much poorer clinical outcome after HSCT with a
conventional conditioning regimen than other class III pa-
tients [84,85]. This subgroup of patients has a very high risk of
GR and regimen-related toxicity. Lower intensity conditioning
is thus required for both these patients and for adults [86].
Conflicting results for transplant-related mortality were ob-
tained when the myeloablative regimen was changed from
busulfan and cyclophosphamide to treosulfan, fludarabine
and thiotepa (TreoFluT), and this change did not improve
GVHD and graft failure in mixed-class groups of patients
[87,88]. However, in well identified groups of class III patients
and, even more significantly, in the subgroup of class III HR
patients, the use of a TreoFluT regimen was associated with
significant improvements in survival and EFS, due to a sig-
nificant decrease in the incidence of sinusoidal obstruction
syndrome (SOS) [89]. In this study, the increase in the risk of
rejection due to the lower intensity of conditioning was
counteracted by the use of peripheral blood stem cells (PBSC)
rather than BM cells. In pediatric class 3 patients, ablation of
the expanded thalassemic marrow and stronger immuno-
suppression through the use of an intensified preparation
regimen including HU, azathioprine, fludarabine and hyper-
transfusion increased event-free survival to 80e85% [90,91].
The use of this protocol in adults did not decrease transplant-
relatedmortality, and thalassemia-free survival remained low
[92]. The inclusion of anti-thymocyte globulin (ATG) in the
preparative regimen of pediatric patients from all classes,
together with the adaptation of busulfan and cyclophospha-
mide concentrations, decreased the incidence of GVHD,
minimized GR and transplant-related mortality and seemed
to abolish the difference between patients from different
Pesaro risk classes, in a recent survey carried out in Greece
and France [93,94]. The transplantation of cord blood (CB) and
bone marrow cells from a MSD offers a similar probability of
long-term cure, but with a lower incidence of GVHD. The
transplantation of PBSC yields lower rates of GR than bone
marrow transplantation in class III patients receiving Treo-
FluT, but GVHD remains a concern when PBSC grafts are
used [95].
One of the main barriers to HSCT with cells from HLA-
identical siblings is the limited availability of donors, which
is, theoretically, 25% for any single sibling. The combined
use of pre-implantation genetic diagnosis and HLA matching
provides a reliable source of stem cells from healthy siblings,
but rates of successful transplantation after ovarian stimu-
lation remain low [96]. For most of the remaining patients,
millions of HLA types are stored in national registries. The
probability of finding an unrelated donor (UD) with 9/10 or
10/10 HLA-matches (HLA-A, -B, -C, eDRB1 and -DQB1) on the
basis of high-resolution typing exceeds 70% for patients of
European ancestry [96], but this likelihood depends on
ethnicity [97]. A prospective study of patients with hemato-
logic malignancies suggested that the transplantation of
cells with this degree of matching from an UD provides a
likelihood of cure similar to that for the transplantation of
cells from a MSD [98]. In both adults and children with b-
thalassemia, bone marrow transplantation from an UD
selected on the basis of high-resolution typing yields success
rates similar to those obtained with a MSD [99,100], but withmore severe GVHD. This approach is not widely used in
adults, due to the high incidence of GVHD, transplant-related
mortality and GR, but it may be used to treat children with
class I/II b-thalassemia safely, provided that ATG is given
[100]. A highly promising recently developed protocol
including marrow reduction and pretransplant immuno-
suppression, followed by low-intensity conditioning with
ATG, has been shown to result in a low risk of toxicity and
durable engraftment in class 3 HR patients receiving cells
from unrelated and related donors; this approach merits
more widespread testing, even in individuals with lower risk
b-thalassemia [101,102].
Donor cells can also be obtained from CB samples. The
transplantation of CB cells originating from HLA-identical
siblings is a viable alternative to the use of adult samples in
class I/II patients [103e105]. Moreover, these cells have the
theoretical advantages of tolerating a higher degree of HLA
incompatibility than adult cells [106] and causing a lower
incidence of acute and chronic GVHD [107]. However, in a
report compiling data from 32 transplant centers from 1996 to
2009, survival and disease-free survival were as low as 62%
and 20%, respectively, in patients with b-thalassemia
receiving CB cells from mismatched donors, after myeloa-
blative conditioning [108]. Graft failure was the chief cause of
treatment failure other than death, which was linked to dis-
ease severity and the use of a non-adapted conditioning
regimen. Multivariate analysis indicated that the principal
factor associated with engraftment was the number of cells
used. These results contrast with those of a Taiwanese study
reporting the survival of 88% of young patients receiving one
or two unrelated CB units after a full myeloablative regimen;
74% of these patients were disease-free five years after
transplantation. Both chronic and acute GVHD occurred, but
most cases were moderate [109]. However, double cord
transplants were performed in this study if a single unit
contained too few nucleated CD34þ cells. More clinical trials
are required.Gene therapy
The concept of gene therapy for beta-thalassemia emerged a
long time ago and was included in a plan for the viable
treatment for hemoglobinopathies as early as 1978 at the
University of California at Los Angeles (UCLA) [110]. However,
major technical issues were encountered and attempts to
demonstrate the efficacy of infusions of transfected mouse
cells in myeloablated animals were far from convincing
[111,112]. The regulatory globin sequences required for high
levels of production [113] and efficient methods for gene
introduction [114] were not available at the time. The stem-
ness properties of the manipulated bone marrow cells were
unknown. Early attempts to treat beta-thalassemia patients
by inserting the b-globin gene into bonemarrow cells, in 1980,
were completely unsuccessful and received an avalanche of
criticism [115,116].
It is essential to achieve a satisfactory combination of high
levels of sustained b-globin expression and the stable propa-
gation of complex sequences. More than 25 years were
required to achieve these goals, which were made possible by
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the b-globin locus regulatory elements and the advent of
lentiviral vectors, which can transfer complex sequences into
hematopoietic stem cells. The genetic elements required for
the adult- and erythroid-specific expression of the b-globin
gene weremapped close to the gene [117,118], in the promoter
region, the second intron and downstream from the poly-
adenylation signal [119e121]. However, the combination of
these elements in a single transgene yielded very low levels of
b-globin gene expression in the erythroid cells of mice un-
dergoing transplantation with genetically modified HSCs
bearing the transgene [122e124]. The discovery of the b-globin
LCR, located in a 15,000-base region far upstream from the
globin genes [125e127], was a major step forward. The use of
this regionmade it possible to design b-globin transgenes that
were strongly expressed in the erythroid cells of transgenic
mice [128,129]. Over a period of 10 years, efforts were made to
delineate the enhancer core elements of the LCR [129,130],
with the aim of decreasing the size of the DNA fragments
used, such that the chimeric DNA constructs would be
compatible with transfer vectors derived from gamma-
retroviruses [131,132]. These vectors provided reasonable
levels of b-globin transgene expression in vitro, but the trans-
duction of mouse hematopoietic stem cells (HSCs) was sub-
optimal, resulting in limited and variable expression of the b-
globin gene in vivo [133,134].
Gamma-retroviral vectors (g-RVs) have three major de-
fects: (i) limited cargo capacity, (ii) instability, and (iii) an
inability to transduce non-dividing cells (most HSCs are
quiescent [135]). These drawbacks precluded the efficient
correction of beta-thalassemia by the infusion of genetically
modified HSCs. As a result, the gene therapy community
working on globin disorders rapidly abandoned the use of g-
RVs shortly after lentiviral vectors (LVs) derived from human
immunodeficiency virus type 1 (HIV1) became available. Not
only were LVs able to transduce cells arrested at the G1-S
boundary of the cell cycle [136,137], they were also able to
transfer much longer sequences than g-RVs [138]. This key
characteristic is dependent on a molecular mechanism for
inhibiting the splicing of the viral RNA before its packaging
into lentiviral particles. This mechanism involves active
transport of the full-length (unspliced) viral RNA from the
nucleus to the cytoplasm by the viral protein REV, which binds
to the REV-responsive element (RRE) located within the viral
RNA structure [139]. The potential utility of incorporating this
mechanism into complex LCR/beta-globin LVs was suggested
by our discovery that unwanted RNA splicing is the key
determinant of LCR/beta-globin g-RV instability and low ti-
ters, and that this problem could be largely corrected by the
removal of undesirable splice sites [131]. Our groups and that
of Sadelain then focused on obtaining proof-of-principle for
the preclinical efficacy of LCR/beta-globin LVs in two mouse
models of beta-hemoglobinopathies: murine beta-
thalassemia [140] and transgenic mouse models of sickle cell
disease [141]. This approach was subsequently consolidated
by other studies [142e146]. For gene therapy for sickle cell
disease, we decided to abandon the wild-type beta-globin
gene, choosing instead to work with a variant we constructed,
with an enhanced ability to inhibit HbS polymerization [141].
This variant (bAT87Q) was generated by introducing the codonfor a specific amino-acid residue present in both the gamma-
and delta-globin proteins (Q, glutamine) to replace the corre-
sponding codon in beta-globin (T, Threonine) [147]. The
bAT87Q variant has an additional key advantage for gene
therapy trials in beta-thalassemia: it facilitates accurate
quantification of the amount of vector-derived beta-globin
produced or present in circulating red blood cells by high-
performance liquid chromatography (HPLC), even in beta-
thalassemia patients receiving red blood cell transfusions or
with bþ-thalassemia [148]. Such quantification is not possible
after the transfer of the wild-type beta-globin gene.
The biosafety of LVs has greatly improved in recent years,
and there is now very little risk of producing replication-
competent lentiviruses [149]. Modifications have included
splitting the genetic elements required for production of the
viral core proteins, the elimination of accessory genes
involved in virus infectivity, the replacement of the viral en-
velope with that of another class of virus, and the removal of
the viral enhancer/promoter elements [150]. Insertional
mutagenesis, which led to leukemia in some patients
receiving g-RV transduced cells [151e154], is a major concern
when integrative vectors are used. Viral transcriptional acti-
vating elements have been shown to trigger oncogene acti-
vation, leading to the strong recommendation that these
elements should be deleted from retroviral vectors used for
gene therapy purposes [155]. LVs have a better safety profile
than g-RVs in hematopoietic cells [156] and are less genotoxic
than g-RVs in transplanted mice [157,158], due to the differ-
ential DNA targeting of the two vectors [159]. Nevertheless,
LVs in general [159], and b-globin-LVs in particular [160],
preferentially integrate into active genes and disturb gene
expression over large distances [161]. Furthermore, the level of
b-globin gene expression under the control of LCR enhancers
is subject to position effects [162,163]. Following vector inte-
gration, levels of b-globin expression have been shown to be
variable and to depend on the location of the vector in the
chromatin in transplantation experiments in mice [164].
Chromatin insulators placed between enhancers and pro-
moters prevent interactions between these elements. They
also buffer transgenes against chromosomal position effects
[165,166]. Chromatin insulators derived from the chicken hy-
persensitive site-4 (cHS4) of the b-globin locus [166] were thus
introduced into b-globin LVs, to increase efficacy and safety
[148,167]. This modification led to a higher probability of b-
globin expression and lower levels of position effect variega-
tion in vitro [167].
A LV encoding the mutated b-globin (bAT87Q) was thus
constructed. In this vector, referred to as LentiGlobin vector
HPV569, the b-globin gene is under the control of the LCR and
the b-globin promoter, and is surrounded by tandem copies of
the cHS4 core element [148]. Experiments in beta-thalassemia
mice subjected to busulfan conditioning and transplantation
with cells transduced with this vector showed them to have
near-normal hemoglobin levels and to display no overall
toxicity [168]. Over the following few years, we performed a
largebodyofexperimentswith theaimofapplying tocarryouta
clinical trial. This involved efficacy and safety/toxicology
studies in mice, and large-scale vector manufacture in good
manufacturing practice (GMP) conditions [148,168e170]. Spe-
cific qualified assays for quality assurance (QA)/quality control
b i om e d i c a l j o u r n a l 3 9 ( 2 0 1 6 ) 2 4e3 830(QC) were also developed and approved by the regulatory au-
thorities. The Sadelain group and several other groups also
worked towards clinical trial applications [171e173]. The dif-
ferences between our own product and trial protocol and those
of theSadelaingroup include (1)differences intheboundariesof
the beta-globin gene, beta-globin promoter and LCR elements,
(2) the initial presence of the cHS4 insulator core in our vector,
(3) an anti-sickling and chromatography-identifiable bAT87Q-
globin variant, (4) differences in vector manufacturing and pu-
rification, (5) full-dose intravenous busulfan treatment, but
without the addition of an immunosuppressive agent, (6)
applicability to both beta-thalassemia and sickle cell disease
due to our choice of the bAT87Q-variant, and (7) initial focus on
betaE/beta0-thalassemia major patients [148,169,170,174]. We
were granted authorization to carry out clinical trials for both
beta-thalassemia and sickle cell disease in 2006 (the LG001
Study), by the French regulatory authority ANSM (Agence
Nationale de Securite du Medicament et des Produits de Sante). In
these trials, we used the GMP-grade HPV569 vector produced
and controlled in the USA. This work [170], together with a
clinical trial of gene therapy for adrenoleukodystrophy [175],
constitutedthefirst trialof theuseofaLVfor thetreatmentofan
inborn genetic disease to be approved anywhere in the world.
The first beta-thalassemia patient to be treated and who
did not receive backup cells was an 18-year-old bE/b0 adult
with clinical beta-thalassemia major who had been
transfusion-dependent and on parenteral iron chelation
therapy since early childhood and had undergone splenec-
tomy at the age of six years, and for whom no HLA-MSD was
available [169,170,174]. Bone marrow cells were processed for
CD34þ cell selection, transduced with the HPV569 lentiviral
vector and thawed for release testing. The patient received an
infusion of 3.9  106 cells/kg after busulfan conditioning at
the fully myeloablative dose (12.8 mg/kg). Hematopoietic
reconstitution was uneventful, and the patient became
transfusion-independent one year after transplantation. He-
moglobin levels are stable, at about 8e9 g/dL 6.5 years later or
7.5 years since gene therapy, with a mean vector copy num-
ber close to 0.2 vector copy per myeloid cell [176]. The
transgenic hemoglobin accounts for one third of total he-
moglobin (HbF, HbE and HbAT87Q). A number of transduced
hematopoietic clones were detected among the lymphoid and
myeloid cells. One dominant clone emerged in month 3 and
stabilized around month 15. This clone accounted for less
than 4% of the peripheral nucleated cells, and this percentage
had fallen to less than 2% five years post-transplantation. In
this clone, the vector was inserted at the high-mobility group
AT-hook 2 (HMGA2) locus, compromising gene splicing and
causing the premature termination of transcription. The
compromised HMGA2 gene displayed transcriptional activa-
tion, generating large amounts of a truncated and active form
of the protein in transduced cells. It was suggested, but not
formally demonstrated, that there was a causal link between
vector insertion at this locus, HMGA2 gene activation, and
clonal dominance [170]. High-performance liquid chroma-
tography (HPLC) analysis of single erythroid colonies indi-
cated that vector-derived bAT87Q-globin expression output
did not differ significantly between the HMGA2 integrant and
colonies displaying integration at other chromosomal sites
[170]. Almost eight years after transplantation, there is nosigns of clonal overgrowth or toxicity [176]. Another patient
underwent transplantation in November 2011, but the vector
copy number was lower. This patient is still transfusion-
dependent, and transgenic hemoglobin levels account for
z5% of total hemoglobin [176].
The first two clinical studies in which LVs were used to
transduce HSCs for the treatment of b-thalassemia [170]
and adrenoleukodystrophy [175] showed that one key re-
striction to fully effective treatment was the limited effi-
cacy of stem cell transduction, which was only 10e20%.
Other studies suggested that the protection provided by the
cHS4 elements was variable [155,177], and dependent on
their position in the chromatin [178]. Furthermore, the
tandem copies of the cHS4 insulator inserted into the b-
globin vector were prone to rearrangement, resulting in the
regeneration of a single element upon vector insertion
[168,179]. This single element had a lower level of
enhancer-blocking activity than the tandem copies [180].
The insertion of insulators into the vector was also shown
to decrease vector titer [179,181]. It therefore seemed likely
that the removal of the cHS4 elements from the vector
would result in a LV with a higher transduction efficacy and
a similar level of safety. We therefore simply removed cHS4
from LentiGlobin vector HPV569 to yield LentiGlobin vector
BB305, which also contains a heterologous promoter to in-
crease vector titers and yield [182]. The production, con-
centration and purification protocols were improved [183].
The new vector BB305 was compared with HPV569 in
human cells and in a comprehensive mouse toxicology
study [182]. It was found to be more effective than the
previous vector, with an equivalent and satisfactory level of
safety [182]. On the basis of these new preclinical results
with LentiGlobin vector BB305 and the sustained positive
outcome for a patient with the parental LentiGlobin vector
HPV569 [170], both the ANSM (French) and the RAC/FDA
(Recombinant DNA Advisory Committee/Federal Drug
Administration, US) granted us approval, in 2013 and 2014,
for three new clinical trials using LentiGlobin vector BB305
sponsored by the biotechnology company bluebird bio: (1)
Trial NCT02151526 (HGB-205) in France, for both beta-
thalassemia and sickle cell disease, (2) Trial NCT01745120
(HGB-204) at multiple centers in the US, Australia and
Thailand, for beta-thalassemia, and (3) Trial NCT02140554
(HGB-206), at multiple centers in the US, for sickle cell
disease. The three trials follow essentially the same clinical
transduction protocol as for the previous trial with Lenti-
Globin vector HPV569, although the BB305 vector is further
purified by preparative chromatography.
Very encouraging results have been obtained for
transfusion-dependent beta-thalassemia major patients, and
were presented by the corresponding clinical investigators at
the annual meeting of the American Society of Hematology
(ASH) in December 2014 [184,185]. For the HGB-205 trial,
transplantationwas carried out in two transfusion-dependent
bE/b0 patients. Six months post-treatment, the mean vector
copynumbers per cellwere above 1 inperipheral blood, andHb
levels had reached 10.2 and 13.4 g/dL, respectively, in the
absence of transfusion, with z70% HbAT87Q, z30% HbE and
low HbF. The two patients became transfusion-independent
10 and 12 days after cell infusion. CD34þ cells from a patient
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ciently, but clinical data were not available in December 2014.
For the HGB-204 study, five transfusion-dependent beta-thal-
assemia major patients underwent transplantation. Two of
thesepatientswere treatedmore than threemonthsbefore the
data were released in December 2014. One of these patients is
bE/b0, whereas the other has the Cooley's anemia b0/b0 geno-
type. Both these patients rapidly became transfusion-
independent, with stable Hb concentrations of 8.6 and 9.6 g/
dL in the absence of transfusion, six and three months post-
transplantation, respectively. The other 3 patients under-
went transplantation inNovember 2014, and too little timehad
elapsed for any meaningful conclusions to be drawn at the
time of data release in December 2014. None of the subjects
experienced a drug product-related adverse event in either of
these trials. Vector integration site analyses showed poly-
clonal reconstitution without clonal dominance. Additional
subjects were still awaiting transplantation in December 2014.
Another clinical trial, sponsored by the Memorial Sloan-
Kettering Cancer Center of New York, USA, was also initi-
ated in 2012, in adult b-thalassemia major patients receiving
autologous CD34þ cells, with non-myeloablative conditioning,
after transduction with the TNS9.3.55 LV from the Sadelain
group (clinicalTrial.gov identifier: NCT01639690) [171,173]. A
non-myeloablative conditioning regimen would clearly have
advantages over a fully ablative regimen, but such a regime
may not currently be sufficient to ensure optimal engraftment
with transduced stem cells. The clinical data from this trial
have yet to be formally released.Conclusion
Future treatments for beta-thalassemia will depend on the
benefit/risk/cost ratios for conventional transfusion and iron
chelation [70], g-globin induction [186], allogeneic bone
marrow transplantation [187] and gene therapy [170], and the
availability of these treatments in the low-income countries in
which most b-thalassemia patients live. Treatments with HU
orwith other g-globin inducers, either alone or in combination,
have been shown to increase Hb levels by 1e5 g/dL [188].
However, HU is currently the only compound approved for the
treatment of adult patients with sickle cell disease. Further-
more, a number of beta-thalassemia patients fail to achieve
significant increases inHbF levels and clinical improvement on
this treatment [44,189]. Most patients with beta-thalassemia
major continue to suffer from profound anemia [69,190] and
new drugs inducing HbF are being investigated [191]. In the
field of hematopoietic stem cell transplantation, Investigations
are continuing, with the aim of extending allogeneic stem cell
infusion to a larger number of patients. The use of hap-
loidentical parent or sibling donors may extend the use of this
treatment to patients lacking a MSD or HLA-compatible UD,
provided that the balance between the risks of GVHD and graft
failure is considered acceptable. Recent successes have been
reported in small series of patients [192e194] and require
confirmation in larger cohorts, with longer periods of follow-
up. Significant improvements in clinical outcomes have been
obtained through progress in the domains of conditioning
regimens, risk stratification and stem cell sources. However,allogeneic stem cell transplantation remains a complicated
and risky procedure. Many of its drawbacks, such as GVHD and
GR in particular, may be avoided by the use of autologous stem
cell transplantation after corrective gene transfer. Gene ther-
apy is still at an early stage of development, but our clinical
trials have already provided proof-of-principle for sustained
clinical efficacy with low toxicity in several patients. With
improvements in the production of LentiGlobin vector BB305,
all of the patients treated rapidly became transfusion-
independent, with near-normal Hb concentrations in the
blood, even in one patient with b0/b0-thalassemia (Cooley's
anemia). Gene therapymay thus become an attractivemode of
treatment for young adults with no MSD considered to be at
low risk of transplant complications. Further studies will be
required before this approach can be offered as a first-line
medical treatment. For high-risk class 3 patients, reduced
and adapted preparative regimensmust be tested. Methods for
selecting and amplifying transduced stem cells may be
required to maximize efficacy in such a context of reduced
conditioning [195]. Finally, although recent gene and cell
therapy trials involving LV-mediated gene transfer in HSCs
followed by autologous cell transplantation gave excellent
outcomes, with no observable toxicity [175,184,196,197], it is
still too early to draw any firm conclusions about the risk of
insertional mutagenesis. Gene vector targeting and gene
modification by homologous recombination [198] remain sub-
optimal, but research is continuing. Combined gene and cell
therapy approaches may make it possible to exploit the pro-
liferative potential of pluripotent stem cells, but many obsta-
cles to the use of such approaches for HSCT remain [199,200].
The next few years will probably confirm the enormous po-
tential of gene transfer methods for the treatment of b-thal-
assemia patients, in terms of both efficacy and safety.Conflicts of interest
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